Vor Biopharma(VOR)
$20.09+0.53 (+2.71%)
VOR
Vor Biopharma financials statements
$20.09
At close:+0.53 (+2.71%)
Want to see VOR full AI Analyst Report?
Vor Biopharma (VOR) Ratios
959 Followers
Vor Biopharma Ratios
VOR's free cash flow for Q3 2026 was $-32.77M. For the 2026 fiscal year, VOR's free cash flow was decreased by $-25.00K and operating cash flow was $-32.75M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 |
| Quick Ratio | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 |
| Cash Ratio | 15.75 | 4.40 | 2.01 | 4.40 | 11.80 |
| Solvency Ratio | -1.10 | -2.45 | -1.94 | -1.70 | -2.56 |
| Operating Cash Flow Ratio | -5.67 | -5.35 | -6.44 | -6.49 | -6.81 |
| Short-Term Operating Cash Flow Coverage | -509.69 | 0.00 | -26.19 | 0.00 | 0.00 |
| Net Current Asset Value | $ -170.33M | $ 50.28M | $ 81.70M | $ 188.19M | $ 188.07M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.22 | 0.17 | 0.13 | 0.07 |
| Debt-to-Equity Ratio | -0.02 | 0.33 | 0.24 | 0.16 | 0.08 |
| Debt-to-Capital Ratio | -0.02 | 0.25 | 0.19 | 0.13 | 0.08 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -2.82 | 1.48 | 1.39 | 1.19 | 1.12 |
| Debt Service Coverage Ratio | -2475.34 | 0.00 | -29.86 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.30 | 9.27 | 10.61 | 19.68 | 9.69 |
| Net Debt to EBITDA | 0.57 | 0.44 | -0.04 | 0.23 | 1.51 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 187.27% | 96.48% | 93.52% | 98.58% | 99.83% |
| Return on Assets (ROA) | -149.96% | -81.82% | -56.17% | -30.76% | -28.40% |
| Return on Equity (ROE) | 423.57% | -120.95% | -78.20% | -36.75% | -31.86% |
| Return on Capital Employed (ROCE) | -84.67% | -97.51% | -64.88% | -32.64% | -29.69% |
| Return on Invested Capital (ROIC) | -84.61% | -94.31% | -63.63% | -32.27% | -29.46% |
| Return on Tangible Assets | -149.96% | -81.82% | -56.17% | -30.76% | -28.40% |
| Earnings Yield | -539.00% | -153.30% | -77.96% | -35.01% | -15.95% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 4.28 | 5.06 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -85.19 | -72.19 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 85.19 | 72.19 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -14.46 | -29.01 | -29.85 | -43.05 | -37.20 |
| Free Cash Flow Per Share | -14.55 | -29.08 | -30.17 | -47.33 | -39.29 |
| Dividend Paid and CapEx Coverage Ratio | -151.66 | -435.20 | -93.82 | -10.06 | -17.76 |
| Capital Expenditure Coverage Ratio | -151.66 | -435.20 | -93.82 | -10.06 | -17.76 |
| Operating Cash Flow Coverage Ratio | -47.57 | -3.13 | -2.81 | -2.19 | -3.84 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -111.25% | -130.98% | -67.05% | -35.59% | -16.91% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.19 | -0.65 | -1.28 | -2.86 | -6.27 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.79 | 0.79 | 1.00 | 1.05 | 2.00 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.90 | -0.76 | -1.49 | -2.81 | -5.91 |
| Price-to-Operating Cash Flow Ratio | -0.90 | -0.77 | -1.51 | -3.09 | -6.25 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.23 | 0.05 | -0.12 | -0.15 |
| Enterprise Value Multiple | 0.38 | -0.23 | -1.36 | -2.94 | -4.89 |
| Enterprise Value | -264.36M | 26.14M | 155.48M | 244.22M | 330.18M |
| EV to EBITDA | 0.38 | -0.23 | -1.36 | -2.94 | -4.89 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 1.84 | -0.26 | -1.53 | -2.61 | -4.52 |
| EV to Operating Cash Flow | 1.85 | -0.26 | -1.55 | -2.87 | -4.78 |
| Tangible Book Value Per Share | -16.64 | 28.14 | 44.86 | 126.72 | 116.35 |
| Shareholders’ Equity Per Share | -16.64 | 28.14 | 44.86 | 126.72 | 116.35 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -70.50 | -34.03 | -35.08 | -46.57 | -37.07 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.21 | 0.85 | 0.85 | 0.92 | 1.00 |
Currency in USD
